0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Brief Communications |

Risk for Valvular Heart Disease among Users of Fenfluramine and Dexfenfluramine Who Underwent Echocardiography before Use of Medication

Christina C. Wee, MD; Russell S. Phillips, MD; Gerard Aurigemma, MD; Stephen Erban, MD, MPH; Gila Kriegel, MD; Marilyn Riley, BS; and Pamela S. Douglas, MD
[+] Article and Author Information

From the Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts; and University of Massachusetts Medical Center and University of Massachusetts Medical School, Worcester, Massachusetts. Acknowledgments: The authors thank Gail Lucey, RN, for coordinating the study at the University of Massachusetts site, Minesh Patel for data collection, Andrea Sweeney-Walsh for performing sonography, and all of the physicians and patients for their participation. Grant Support: Dr. Wee is supported by a National Research Service Award training grant (#5 T32 PE11001). Requests for Reprints: Christina C. Wee, MD, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Libby 330, Boston, MA 02215; e-mail, cweekuo@bidmc.harvard.edu. Current Author Addresses: Drs. Wee, Phillips, and Kriegel: Division of General Medicine, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215. Dr. Douglas and Ms. Riley: Division of Cardiology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215. Dr. Erban: Division of General Medicine, University of Massachusetts Memorial Health Care, 55 Lake Avenue North, Room A3-139, Worcester, MA 01655. Dr. Aurigemma: Division of Cardiology, University of Massachusetts Medical Center, S3-860, 55 Lake Avenue North, Worcester, MA 01655.


Copyright ©2004 by the American College of Physicians


Ann Intern Med. 1998;129(11_Part_1):870-874. doi:10.7326/0003-4819-129-11_Part_1-199812010-00005
Text Size: A A A

Background: Because uncontrolled echocardiographic surveys suggested that up to 30% to 38% of users of fenfluramine and dexfenfluramine had valvular disease, these drugs were withdrawn from the market.

Objective: To determine the risk for new or worsening valvular abnormalities among users of fenfluramine or dexfenfluramine who underwent echocardiography before they began to take these medications.

Design: Cohort study.

Setting: Academic primary care practices.

Patients: 46 patients who used fenfluramine or dexfenfluramine for 14 days or more and had echocardiograms obtained before therapy.

Measurements: Follow-up echocardiography. The primary outcome was new or worsening valvulopathy, defined as progression of either aortic or mitral regurgitation by at least one degree of severity and disease that met U.S. Food and Drug Administration criteria (at least mild aortic regurgitation or moderate mitral regurgitation).

Results: Two patients (4.3% [95% CI, 0.6% to 14.8%]) receiving fenfluramine-phentermine developed valvular heart disease. One had baseline bicuspid aortic valve and mild aortic regurgitation that progressed to moderate regurgitation. The second patient developed new moderate aortic insufficiency.

Conclusion: Users of diet medications are at risk for valvular heart disease. However, the incidence may be lower than that reported previously.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)